Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites
Article first published online: 15 SEP 2011
© 2011 The Japan Society of Hepatology
Volume 41, Issue 11, pages 1017–1024, November 2011
How to Cite
Deng, L. and Tang, H. (2011), Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites. Hepatology Research, 41: 1017–1024. doi: 10.1111/j.1872-034X.2011.00873.x
- Issue published online: 27 OCT 2011
- Article first published online: 15 SEP 2011
- Received 22 April 2011; revision 6 July 2011; accepted 8 July 2011.
- chronic hepatitis B;
- drug resistance;
- hepatitis B virus;
- nucleos(t)ide analogs
Nucleos(t)ide analogs (NAs) have become the mainstream drugs for the treatment of chronic hepatitis B virus infection. Drug resistance to NAs, however, has posed a major obstacle in obtaining sustained viral suppression. Standardized definitions of terms and nomenclature in discussing NAs resistance have been proposed. Drug resistance to NAs is produced by a combination of viral, host and antiviral drug factors. A detailed understanding of the mechanisms and effects of mutation sites that cause resistance to NAs is important for the design of rational treatment and management of patients with existing drug resistance.